The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability to isolate specific cell types from heterogeneous tissue or blood-derived sources such as whole peripheral blood, bone marrow, or cord blood is critical to advancing […]
By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is impressive given that the first CAR-T therapies only gained US Food and Drug Administration (FDA) approval in 2017 and demonstrates the power of these new […]
After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously intractable cancers and diseases (Figure 1). Since 2017, six CAR-T cell therapies have been approved by the Food and Drug Administration (FDA) and all are […]
T cells are the main effector cells of the adaptive immune system and can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on their cell surface. Differentiated from bone marrow-derived hematopoietic stem cells, T cells migrate from the thymus gland where they mature into CD4+ and CD8+ T […]
Re-tasking our body’s own immune system to treat cancer has been a major scientific goal over the last few decades. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. One of the most revolutionary approaches to date […]
Re-tasking our body’s own immune system to treat cancer has been a major scientific goal over the last few decades. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 20181. One of the most revolutionary approaches to date […]
